| Similar Articles |
|---|
 |
The Motley Fool
November 9, 2006
Brian Lawler |
Hospira's Flatlining Sales There's no good news to be found in this medical products supplier's medicine chest. The upcoming fourth quarter isn't going to be any better, either. Investors, take note.   |
The Motley Fool
May 13, 2005
Brian Gorman |
Hospira's Hopeful Signs The medical products company's strong quarter belies a less exciting future. Investors should probably take a wait-and-see attitude. |
The Motley Fool
June 2, 2005
Brian Gorman |
Hospira's Little Purchase There may be more to Hospira's recent acquisition than meets the eye. |
The Motley Fool
March 1, 2007
Brian Lawler |
Hospira's Boring Growth The medical products provider announces its fourth quarter financial results and gives guidance for 2007. Investors, take note. |
BusinessWeek
May 31, 2004
Robert Barker |
Hospira Just May Put You In The Pink If the Abbott Laboratories spin-off's first steps hardly seem promising, that's one reason why I see the company as worth much more of the intelligent investor's attention than the long calendar of pending tech and biotech IPOs. |
The Motley Fool
November 10, 2005
Stephen D. Simpson |
Hospitable Treatment for Hospira Solid margins fuel strong earnings at the hybrid generics - medical distributor. Buying this stock wisely may be the key to good long-term returns. |
The Motley Fool
January 20, 2011
Jeremy Phillips |
Time to Sell Hospira? Hospira has failed two of the quick tests that would make it a sell. This is great, but does it mean you should hold your Hospira shares? |
The Motley Fool
August 8, 2007
Ryan Fuhrmann |
Hospira Looks to Deliver Will a recent acquisition boost drug delivery firm Hospira's growth prospects? The new Mayne Pharma Limited division played a primary role in delivering an impressive 30% reported sales growth. |
The Motley Fool
November 11, 2004
Brian Gorman |
Hospira's Possibilities The medical products and services outfit is not flashy, but it may benefit from long-term trends. Their stock may be worth monitoring. |
The Motley Fool
August 10, 2006
Stephen D. Simpson |
Volatility, Thy Name Is Hospira Margins continue to stand in the way of consistent performance at the health-care company. Investors, take note. |
The Motley Fool
September 22, 2006
Brian Lawler |
Hospira's New Mate Down Under The specialty injectable pharmaceutical announces an acquisition, but the move means adding on a lot more debt. Investors, take note. |
The Motley Fool
May 9, 2006
Stephen D. Simpson |
Riding the Hospira Yo-Yo There's a solid foundation on this roller coaster pharmaceutical and drug delivery company. Maybe Hospira's current valuation doesn't make it a "gem," but that's not really within its control. |
The Motley Fool
January 5, 2010
Brian Orelli |
A Deal Manufactured by Necessity Genzyme gets some help from a new friend. |
The Motley Fool
February 23, 2004
Brian Gorman |
Abbott Cleans Up Its Act Abbott closes the books on its problems with the FDA and clears the way to a spinoff. Abbott finally passed FDA muster with its Illinois diagnostics plant. Its multi-year problem highlights the importance of investors monitoring manufacturing while watching a pharmaceutical company's pipeline. And with its FDA compliance issues behind it, Abbott can look forward to spinning off its Hospital Products Division. |
The Motley Fool
January 18, 2007
John Finneran |
Sturdy State Street State Street has delivered solid performance for 215 years. Again and again, this firm has proven that a seemingly boring business can still be beautiful to investors. |
The Motley Fool
July 19, 2005
Stephen D. Simpson |
Peek-a-Boo ICU ICU Medical has taken on quite a bit of risk in the process of remaking the company. It's best to wait for a reasonable valuation before buying shares. |
The Motley Fool
February 26, 2008
Alyce Lomax |
Gray Days for Tar-jay? There's nothing too surprising about Target's fourth-quarter results, given all the signs of consumer spending slowdown. |
The Motley Fool
November 20, 2006
Brian Gorman |
Hospira's Bold Move The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff. |
InternetNews
January 14, 2008
Larry Barrett |
SAP: 4Q Sales Better Than Expected But Margins Slide SAP joined IBM in giving investors a reason to celebrate - for now. |
The Motley Fool
September 2, 2009
Brian Orelli |
Should You Buy This Spinoff? Cardinal Health kicks its baby out of the nest. |
IndustryWeek
September 1, 2006
David Blanchard |
Hospira CEO Chris Begley -- Diagnosis: Green and Lean Chris Begely says manufacturers should become more environmentally responsible. What's more, he's doing something about it. |
The Motley Fool
January 18, 2012
Sean Williams |
Are These 2 Medical Device Makers Takeover Targets? Could these two medical device makers put themselves up for sale in 2012? |
